Title : Real-world virological efficacy and safety of daclatasvir/asunaprevir/beclabuvir in patients with chronic hepatitis C virus genotype 1 infection in Japan.

Pub. Date : 2019 Aug

PMID : 30848363






6 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 RESULTS: More than 60% of patients had a history of failure to achieve SVR with interferon (IFN)-free DAA therapy. daa interferon alpha 1 Homo sapiens
2 Multivariate analysis identified a history of failure with IFN-free DAA therapy and pretreatment HCV RNA levels as factors significantly associated with treatment failure. daa interferon alpha 1 Homo sapiens
3 Whereas the SVR rate in patients without a history of IFN-free DAA therapy was 91.7% (33 of 36 patients), it was only 30.9% (17 of 55 patients) among patients with a history of IFN-free DAA therapy. daa interferon alpha 1 Homo sapiens
4 Whereas the SVR rate in patients without a history of IFN-free DAA therapy was 91.7% (33 of 36 patients), it was only 30.9% (17 of 55 patients) among patients with a history of IFN-free DAA therapy. daa interferon alpha 1 Homo sapiens
5 CONCLUSIONS: Many patients treated with the DCV/ASV/BCV regimen have a history of a failure to achieve SVR with previous IFN-free DAA therapy. daa interferon alpha 1 Homo sapiens
6 SVR rate was not as high as that in pre-approval clinical trial of this regimen in IFN-free DAA-naive patients. daa interferon alpha 1 Homo sapiens